Organization
St. Louis, MO
17 abstracts
Abstract
Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).Org: Columbus, OH, GZA-ZNA Hospitals, Joan and Sanford I Weill Medical College of Cornell University, Weill Cornell Medicine, New York, NY,
Abstract
ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Malden, MA,
Abstract
Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).Org: University of Wisconsin Carbone Cancer Center, Madison, WI, Dana-Farber Cancer Institute, Boston, MA, University of Wisconsin,
Abstract
High deductible health plans and survival among cancer survivors.Org: Department of Radiation Oncology, Washington University School of Medicine in St. Louis, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, Costs of Care, Boston, University of Minnesota Masonic Cancer Center, University of California, San Francisco,
Abstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.Org: University of Kansas Medical Center, Mayo Clinic, Mayo Clinic Cancer Center, Washington University in St. Louis, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute,
Abstract
A stepped wedge trial of a healthcare provider–focused intervention to increase human papillomavirus (HPV) vaccine initiation among survivors of childhood cancer.Org: Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, NC, Emory University, Atlanta, GA, USA, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, Emory University and Children's Healthcare of Atlanta, Atlanta, GA,
Abstract
Evaluation of the tumor microenvironment in African American and non-Hispanic White patients with non-small cell lung cancer associated with PD-L1 expression or the presence of tertiary lymphoid structures.Org: Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, Washington University School of Medicine in St. Louis, St. Louis, MO,
Abstract
A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.Org: City of Hope Comprehensive Cancer Center, Duarte, CA, Washington University School of Medicine in St Louis, St. Louis, MO, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Characterization of ESR1 mutations in endometrial and ovarian cancers.Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, Johns Hopkins Kimmel Cancer Center, Caris Life Sciences, Irving, TX,
Abstract
Single-center retrospective analysis of safety and efficacy of dose-reduced enfortumab vedotin (EV) in frail patients with metastatic urothelial carcinoma (mUC).Org: Washington University School of Medicine in St Louis, St. Louis, MO,
Abstract
Interim results from a phase I/II study of duvelisib PI3Kδγ inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy.Org: University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA, Washington University School of Medicine in St Louis, St. Louis, MO, Department of Immunology and Oncology, Clínica Universidad de Navarra,
Abstract
Multi-factor dynamic analysis of ctDNA and CTC to aid the diagnostic prognosis of patients with metastatic breast cancer (MBC).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, CTC Core Facility, Lurie Cancer Center,
Abstract
Examining the potential for lead-time bias by estimating stage-specific proportions of deaths due to diagnosed cancer.Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Illumina, Inc., Menlo Park, CA, Washington University School of Medicine in St Louis, St. Louis, MO,
Abstract
From the lab to the clinic: Lessons learned from a translational working group.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Division of Surgical Oncology, Department of Surgery, The Ohio State University, Durham, NC, COMET Study Patient Leadership Team, San Francisco, CA,
Abstract
Healthcare coverage, access, and affordability among adult immigrant cancer survivors in the United States.Org: Memorial Sloan Kettering Cancer Center, New York, NY, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Washington University School of Medicine in St. Louis, St. Louis, MO,
Abstract
A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer whose disease progressed on gemcitabine-based therapy.Org: Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, Washington University School of Medicine in St Louis, St. Louis, MO, Washington University School of Medicine in St. Louis, Dartmouth Hitchcock Medical Center,